Welcome to February’s On Rotation!
Wondering who’s in and who’s out at major health companies, startups, hospitals, and more? We’ve got you covered.
Here’s a noncomprehensive roundup of the past month’s career shifts.
Have a job announcement to share? Drop Caroline or Cassie an email at [email protected] or [email protected].
José (Joe) Almeida: Medtech company Baxter International’s chair, president, and CEO retired effective immediately after nearly a decade at the helm, the company announced on Feb. 3. He will continue in an advisory capacity through the end of October. The board of directors appointed lead independent director Brent Shafer as chair and interim CEO until a permanent replacement is found.
Molly Biwer: Biwer left her position at Rochester, Minnesota-based Mayo Clinic as chair and SVP of marketing, brand strategy, advertising, and enterprise strategic partnerships this month to join Atlanta-based Emory Healthcare as chief marketing officer, the health system announced on Feb. 19.
Albert Bourla: Pfizer’s chairman and CEO isn’t leaving the pharma giant, but he is adding another feather to his cap. PhRMA, the industry’s largest trade group, announced on Feb. 19 that Bourla would join as board chair after the departure of Daniel O’Day, chairman and CEO of Gilead Sciences.
Will Byington: TriValence, a healthcare services company founded in 2022, announced Byington as CEO on Feb. 18. He previously held leadership roles at Cloudmed, an R1 company, and Vizient, a healthcare performance improvement company, according to his LinkedIn profile.
Patrizia Cavazzoni: Pfizer named the former director of the FDA’s Center for Drug Evaluation and Research as its new chief medical officer and EVP on Feb. 24, replacing Aida Habtezion. Cavazzoni’s appointment has gotten some…mixed reviews, to say the least, amid concerns about the relationship between Big Pharma and the agency that regulates it.
Navigate the healthcare industry
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
Christopher McGinnis: GoodRx appointed McGinnis as its new CFO, effective Feb. 4. McGinnis joins following a stint as CEO of CitizensRx, a pharmacy benefit management provider.
Maeve O’Meara: On Feb. 4, O’Meara was promoted from president to CEO of ParetoHealth, a health benefits company for small and mid-size employers that offers an alternative to traditional health insurance. She’s replacing Andrew Cavenagh, the company’s co-founder, who will move from being CEO to executive chairman.
Paul Owen: Venture capital firm Flagship Pioneering announced Owen as CEO-Partner of Flagship and CEO of YourBio Health, a remote blood collection technology company founded by Flagship in 2011, on Feb. 19. Owen’s most recent job was board director and president of Oncodea, an early cancer detection company, according to a release.
Kimberly Stegmaier: On Feb. 19, Boston’s Dana-Farber Cancer Institute announced Stegmaier as its new chair of pediatric oncology as well as associate chief of the hematology/oncology division at Boston Children’s Hospital. She’s currently a professor of pediatrics at Harvard Medical School and holds a number of other leadership roles at Dana-Farber. She will transition to these new roles on April 1, succeeding Scott Armstrong, who was recently appointed SVP for drug discovery and chief research strategy officer at Dana-Farber, the institute said in a press release.
Nitza Thomasson: Global pharmaceutical group Servier announced Thomasson on Feb. 27 as executive director of neurology R&D, effective March 1. Thomasson has a PhD in neuroscience and is the co-founder of biopharmaceutical companies BrainEver and GenSight Biologics, the release said.